Cite
Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).
MLA
Hata, Akito, et al. “Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).” Clinical Lung Cancer, vol. 19, no. 6, Nov. 2018, pp. e865–69. EBSCOhost, https://doi.org/10.1016/j.cllc.2018.07.009.
APA
Hata, A., Katakami, N., Shimokawa, M., Mitsudomi, T., Yamamoto, N., & Nakagawa, K. (2018). Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-small-cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L). Clinical Lung Cancer, 19(6), e865–e869. https://doi.org/10.1016/j.cllc.2018.07.009
Chicago
Hata, Akito, Nobuyuki Katakami, Mototsugu Shimokawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, and Kazuhiko Nakagawa. 2018. “Docetaxel Plus RAmucirumab With Primary Prophylactic Pegylated Granulocyte-ColONy Stimulating Factor Support for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L).” Clinical Lung Cancer 19 (6): e865–69. doi:10.1016/j.cllc.2018.07.009.